LONDON, July 05, 2019 – Ascension Healthcare plc (“Ascension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for haemophilia and osteoarthritis, today announces it will be attending the 27th International Society of Thrombosis and Haemostasis (ISTH) Congress, taking place in Melbourne, Australia, from Saturday 6th July to Wednesday 10th July.
The congress brings together some of the world’s leading experts in thrombosis, haemostasis and vascular biology to discuss the latest developments and clinical applications designed to improve patient care.
If you would like to arrange a meeting with either Dr Gavin Ling, Chief Medical Officer or Dr Sam Yurdakul, Development Director, please contact [email protected].
Ascension Healthcare plc is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for the treatment of haemophilia and osteoarthritis. The Company has three products in clinical development for the treatment of haemophilia A and also a range of internationally marketed products for osteoarthritis sufferers. For more information please visit: www.ascension.co.uk/
For more information contact
Ascension Healthcare plc
Biresh Roy, Chief Executive Officer
[email protected] / +44 (0)20 7291 5400
Consilium Strategic Communications
(European Media and Investor Enquiries)
Lindsey Neville, Ashley Tapp
Tel: +44 (0)20 3709 5700 / [email protected]